目的：在这项试点临床研究中，我们报道了来自两种黑色酵母金黄色葡萄球菌AFO-202和N-163的β-葡聚糖对COVID-19患者细胞因子风暴和凝血病生物标志物的有益作用.
方法：将24例RT-PCR阳性的COVID-19患者随机分为3组（Gr）：Gr。1个对照(n=8)-标准治疗;Gr。图2:标准处理+AFO-202β葡聚糖(n=8);和Gr。3,标准处理+AFO-202和N-163β葡聚糖的组合(n=8),持续30天。
结果：所有组的受试者均无死亡或需要通气。Gr中D-二聚体值（751ng/ml至143.89ng/ml）和IL-6值（7.395-3.16pg/ml）降低。15天为1，但在第30天水平升高至异常水平（D-二聚体：202.5ng/ml；IL-655.37pg/ml）；第2组（D-二聚体：560.99ng/dl至79.615；IL-6：26.18-3.41pg/ml）和第3组（D-二聚体：1614ng/dl至164.25ng/dl；IL-6：0.5：对于ESR观察到相同的趋势。在Gr中，LCR和LeCR显著增加，而NLR显著降低。3.CD4+和CD8+T细胞计数在Gr.3显示相对较高的增加。组间CRP无差异。
结论：由于这些β-葡聚糖是众所周知的食品补充剂，具有良好的安全性记录，建议进行更大规模的多中心临床研究,以验证它们在COVID-19和随之而来的长COVID-19综合征的治疗中的辅助作用.
OBJECTIVE: In this pilot clinical
study, we report the beneficial effects of beta glucans derived from two strains AFO-202 and N-163 of a black yeast
Aureobasidium pullulans on the biomarkers for cytokine storm and coagulopathy in COVID-19 patients.
METHODS: A total of 24 RT-PCR positive COVID-19 patients were recruited and randomly divided into three groups (Gr): Gr. 1 control (n = 8) - Standard treatment; Gr. 2: Standard treatment + AFO-202 beta glucan (n = 8); and Gr. 3, Standard treatment + combination of AFO-202 and N-163 beta glucans (n = 8) for 30 days.
RESULTS: There was no mortality or requirement of ventilation of the subjects in any of the groups. There was a decrease in D-Dimer values (751 ng/ml to 143.89 ng/ml) and IL-6 values (7.395-3.16 pg/ml) in Gr. 1 in 15 days but the levels increased to abnormal levels on day 30 (D-Dimer: 202.5 ng/ml; IL-6 55.37 pg/ml); which steadily decreased up to day 30 in groups 2 (D-dimer: 560.99 ng/dl to 79.615; IL-6: 26.18-3.41 pg/ml) and 3 (D-dimer: 1614 ng/dl to 164.25 ng/dl; IL-6: 6.25-0.5 pg/ml). The same trend was observed with ESR. LCR and LeCR increased while NLR decreased significantly in Gr. 3. CD4 + and CD8 + T cell count showed relatively higher increase in Gr.3. There was no difference in CRP within the groups.
CONCLUSIONS: As these beta glucans are well known food supplements with a track record for safety, larger multi-centric clinical studies are recommended to validate their use as an adjunct in the management of COVID-19 and the ensuing long COVID-19 syndrome.
PDF(Pubmed)